Altogether, this study provides valuable insights into surmounting GBM immunotherapy resistance and highlights the promise of potential combination therapies involving anti-PD1/PDL1 and the standard of care for GBM patients characterized by high Treg cell accumulation. This evidence concerns the gene CD274 and glioblastoma.